Exit Interviews Exploring Patients’ Experience of Change in Crohn’s Disease Symptoms During the Mirikizumab Phase 3 Clinical Trial In Adult Patients With Moderately-to-Severely Crohn’s Disease
The Urgency NRS, CDAI-SF, and CDAI-AP are content-valid patient-reported outcome measures in Crohn's disease. The PGRS/PGIC are conceptually related global assessments of bowel urgency, stool frequency, and abdominal pain. Patients considered reduction in these symptoms as meaningful and remission.
Authors
- Katie Mellor (ORCID: https://orcid.org/0000-0002-4054-5975)
- Harriet Makin (ORCID: https://orcid.org/0000-0002-1769-2205)
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
- Jake Macey (ORCID: https://orcid.org/0000-0003-2697-0438)
- Helen Kitchen (ORCID: https://orcid.org/0000-0001-5519-0794)
- Radu Roşu (ORCID: https://orcid.org/0000-0002-6400-3169)
- Emily Hon
Institutions
- Eli Lilly (United States) (US)
- Clarivate (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1093/crocol/otae079
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- Eli Lilly and Company